World Health Organisation director-general Tedros Adhanom Ghebreyesus. Picture: REUTERS/FABRICE COFFRINI
World Health Organisation director-general Tedros Adhanom Ghebreyesus. Picture: REUTERS/FABRICE COFFRINI

For months, the World Health Organisation (WHO) has called on countries to come together to ensure a fair distribution of Covid-19 vaccines among rich and poor nations. Now it’s starting to lose patience.

On Monday, WHO director-general Tedros Adhanom Ghebreyesus said drug manufacturers had prioritised regulatory approval in rich countries, where profits are highest, rather than submitting full dossiers to get the greenlight from the global health body. He said this could delay distribution through Covax, a WHO-backed initiative that aims to supply vaccines to poorer countries.

“The world is on the brink of a catastrophic moral failure,” Tedros said. “Even as they speak the language of equitable access, some countries and companies continue to prioritise bilateral deals — going around Covax, driving up prices and attempting to jump to the front of the queue. This is wrong.”

The WHO’s struggles have opened the door for China to start ramping up its vaccine diplomacy, with foreign minister Wang Yi pledging last week to hand out more than a million doses during a swing through Southeast Asia. That amounted to a geopolitical win just before the inauguration of US president-elect Joe Biden, who has vowed to put the US back in the WHO after Donald Trump’s withdrawal from the organisation in 2020.

“China’s ‘mask diplomacy’ in 2020 is being followed in 2021 by ‘vaccine diplomacy’,” said Ian Storey, a senior fellow at the Iseas-Yusof Ishak Institute. “The aims remain the same: to win friends and influence countries in Southeast Asia and bury the memory that the pandemic started in China a year ago.”

China’s vaccines have received some high-profile endorsements, with Indonesian President Joko Widodo receiving the Sinovac Biotech shot on live television last week in the world’s fourth-most populous nation, despite inconsistent efficacy data. Brazil also began distributing 6-million Sinovac doses on Monday — an about-face for President Jair Bolsonaro, who had been an outspoken critic of Chinese vaccines in 2020.

‘Can no longer wait’

Cambodian Prime Minister Hun Sen, who said in December that his country wouldn’t use any vaccines that weren’t approved by the WHO, last week reversed course and accepted 1-million vaccine doses from China. He cited widespread use in places such as Indonesia, Egypt and China, noting that Wang had received the vaccine and is still “in good health and can travel to places”.

“For the need to defend our nation and protect our people from this deadly epidemic, we can no longer wait,” Hun Sen said in a message published in a cabinet newsletter on Friday. “We are reversing what I said last time about accepting only vaccines recognised by the WHO.”

Because they lack regulatory bodies with the capacity to scrutinise scientific data, many developing countries have traditionally relied on the WHO’s list of approved vaccines to know which shots they can permit for local vaccination drives.

At the end of 2020, the Pfizer-BioNTech vaccine was the first, and so far only, shot to receive emergency validation from the WHO since the outbreak began a year ago. With no low-income countries producing their own vaccines, richer nations have secured 85% of Pfizer’s vaccine and all of Moderna’s, according to London-based research firm Airfinity.

While China has pledged to support the WHO’s efforts, its vaccines are not among those procured by Covax. A spokesperson for Sinovac said the company has began submitting data to the WHO for a pre-qualification of its coronavirus vaccine, CoronaVac. A group of WHO inspectors has also traveled to China and will inspect its production facilities after completing quarantine, the spokesperson said.

Covax still plans to distribute 2-billion doses around the world by the end of 2021, with enough to protect 3% of the population in all participating countries by July, according to an e-mailed response to questions.

Among the 11 candidates that it can tap for distribution, two — Moderna’s shot, and the one developed by AstraZeneca and the University of Oxford — are ready for rollout and are being administered in countries such as the US and UK. It’s unclear why Covax has not yet started distributing those vaccines as well.

Tedros’s statements castigating companies for prioritising rich countries where they can make the most profit indicates that the global health body sees the delay as stemming from the corporates’ end.

AstraZeneca said on December 30 that it was seeking the WHO’s greenlight, the body’s emergency use listing, “for an accelerated pathway to vaccine availability in low- and middle-income countries”. A company spokesperson did not immediately respond to a request for comment about the stage to which the process has progressed.

Covax’s rollout could begin “as early as February, pending favourable regulatory outcomes and the readiness of health systems and national regulatory systems in individual participating economies”, said Iryna Mazur, a spokesperson at Gavi, the global vaccine alliance, which is co-leading Covax.

Thailand bought 2-million doses from Sinovac, and China promised to donate 800,000 doses to the Philippines and Myanmar during Wang’s diplomatic push last week.

During a visit to Manila, Wang drew praise from Philippine officials after committing to completing China-funded infrastructure projects including a $400m bridge and a $940m cargo railway project.

This week, Philippine President Rodrigo Duterte chided a group of senators who scrutinised the government’s plans to buy Sinovac, after previously threatening to terminate a visiting forces agreement with the US if it failed to deliver at least 20-million vaccines immediately. “No vaccine, no stay here,” Duterte said last month of the military deal — a threat he has made before without following through on.

“Coronavirus vaccines have clearly become a political football in the increasing US-China cold war,” said Paul Chambers of Naresuan University’s Centre of Asean Community Studies, who has researched geopolitics in Southeast Asia for about two decades. “China is using the daunting delay in launching Covax to initiate and expand its supply of Sinovac to developing countries.”

Bloomberg

Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.